March 16, 2020 / 9:37 PM / 16 days ago

BRIEF-Fortress Biotech Reports Fourth Quarter Financial Results

March 16 (Reuters) - Fortress Biotech Inc:

* FORTRESS BIOTECH REPORTS RECORD FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

* FORTRESS BIOTECH - NDA FOR IV TRAMADOL ACCEPTED FOR REVIEW BY FDA; PDUFA DATE IS SET FOR OCT 10, 2020

* FORTRESS BIOTECH - ROLLING NDA SUBMISSION FOR CUTX-101 FOR TREATMENT OF MENKES DISEASE IS ON TRACK TO BEGIN IN Q4 2020

* FORTRESS BIOTECH - Q4 REVENUES GENERATED FROM FIVE MARKETED SPECIALTY DERMATOLOGY PRODUCTS WERE $11.1 MILLION, REPRESENTING 85% GROWTH OVER Q4 2018

* FORTRESS BIOTECH - LOOK FORWARD TO CONTINUED ACQUISITIONS OF MARKETABLE DERMATOLOGY DRUGS, IN-LICENSES OF DEVELOPMENT-STAGE DRUG CANDIDATES

* FORTRESS BIOTECH - EXPECT TO LAUNCH ONE TO TWO NEW PRESCRIPTION DRUGS IN MARKETED DERMATOLOGY PRODUCTS CATEGORY IN 2020

* FORTRESS BIOTECH - CAELUM RECEIVED FDA FEEDBACK THAT SUPPORTS INITIATING PHASE 2/3 PROGRAM FOR CAEL-101, WHICH IS EXPECTED TO BEGIN IN H1 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below